Bad expression predicts outcome in patients treated with tamoxifen

By Cannings Elizabeth   Kirkegaard Tove   Tovey Sian M.   Dunne Barbara   Cooke T.   Bartlett John M.  

Breast Cancer Research and Treatment, Vol. 102, Iss. 2, 2007-04 ,pp. : 173-179

Springer Publishing Company

Access to resources Recommend Favorite

Expression of sex steroid receptor subtypes in normal and malignant breast tissue – a pilot study in postmenopausal women

By Löfgren L.   Sahlin L.   Schoultz B. Von   Fernstad R.   Skoog L.   Schoultz E. Von  

Acta Oncologica, Vol. 45, Iss. 1, 2006-02 ,pp. : 54-60

Informa Healthcare

Access to resources Recommend Favorite

Estrogen and Progesterone Receptor Expression in Postmenopausal Tamoxifen-Exposed Endometrial Pathologies

By Cohen I.   Beyth Y.   Altaras M.M.   Shapira J.   Tepper R.   Cardoba M.   Yigael D.   Figer A.   Fishman A.   Berenhein J.  

Gynecologic Oncology, Vol. 67, Iss. 1, 1997-10 ,pp. : 8-15

Elsevier

Access to resources Recommend Favorite

Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer

By Sabine Vicky  

Breast Cancer Research and Treatment, Vol. 122, Iss. 2, 2010-07 ,pp. : 419-428

Springer Publishing Company

Access to resources Recommend Favorite

Differential mRNA Expression of Urokinase-Type Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor Type-2 in Normal Human Endometria and Endometrial Carcinomas

By Foca C.   Moses E.K.   Quinn M.A.   Rice G.E.  

Gynecologic Oncology, Vol. 79, Iss. 2, 2000-11 ,pp. : 244-250

Elsevier

Access to resources Recommend Favorite